Navigation Links
FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
Date:6/14/2011

SILVER SPRING, Md., June 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The test, called Inform Dual ISH, allows for measurement of the number of copies of the HER2 gene in tumor tissue. The HER2 gene is located on chromosome 17 in human cells. An excessive amount of the protein produced by the gene is found in some types of cancer cells, including breast cancer cells.

The Inform Dual ISH test allows lab personnel to count the number of copies of HER2 genes on chromosome 17 in a small sample of the breast tumor. The sample is stained with chemicals that cause copies of HER2 genes and chromosome 17 to change color. Copies of the HER2 gene appear black and copies of chromosome 17 appear red. These color changes can be seen under a standard microscope.

This feature allows lab personnel to see and count copies of chromosome 17 and HER2 genes on the same slide, similar to HER2 amplification measurements that have traditionally only been available using fluorescence microscopes. The Inform Dual ISH, however, allows lab staff to see the HER2 and chromosome 17 signals directly under a microscope, for longer periods of time.

"When used with other clinical information and laboratory tests, this test can provide health care professionals with additional insight on treatment decisions for patients with breast cancer," said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostic Device Evaluation and Safety in the FDA's Center for Devices and Radiological Health.

The FDA based its approval of the Inform Dual ISH on a U.S. study involving tumor
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
(Date:10/17/2014)... , Oct. 17, 2014  Hanger, Inc. (NYSE: ... report its results of operations for the quarter ended ... the market closes.  A conference call to discuss these ... on Friday, November 7, 2014. Those wishing to participate ... Friday, November 14, 2014 by dialing 1-855-859-2056 and referencing ...
(Date:10/17/2014)... UBM Medica US announces that Neurology ... information resource for neurologists and other healthcare providers, features special ... , with discussions of the latest developments in approaches to ... Parkinson disease , more than the total of those who ... disease. Diagnosis can be difficult because there are no confirmatory ...
Breaking Medicine Technology:Early Key Findings from the Medical Affairs Consortium Research 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... March 16, 2011 Working with the Foundation of UMDNJ ... in Moscow, Russia, has donated $100,000 to fund the research ... of Pharmacology at UMDNJ-Robert Wood Johnson Medical School (RWJMS) and ... The Blue Sky Research and Development Fund in ...
... LAKE CITY, March 16, 2011 Dynatronics Corporation (Nasdaq: ... selected for inclusion in the RB Milestone Portfolio, a ... ("RBMG"), to be introduced to the market via a ... including equity research, The Portal Network™, and non-deal roadshows, ...
Cached Medicine Technology:International Biotech Firm Funds Research Into Aging Through Foundation of UMDNJ 2Dynatronics Selected for Inclusion in RB Milestone Portfolio 2
(Date:10/20/2014)... The Advocator Group, LLC is proud ... for Suicide Prevention’s (AFSP) Out of the Darkness walk ... that hosts hundreds of community walks throughout the country ... to help understand and prevent suicide through not only ... , The Advocator Group shares this passion for ...
(Date:10/20/2014)... 2014 hc1.com today announced the ... solution that enables healthcare organizations of all sizes ... customer relationship management (“CRM”) solution. , Designed from ... of the healthcare industry, the hc1 Healthcare Relationship ... patients by combining healthcare CRM, HIPAA-compliant collaboration, and ...
(Date:10/20/2014)... Principle Business Enterprises, a family owned ... top-of-the-line absorbent products. The company has recently made ... brand, Tranquility® Premium Protection absorbent products. The company ... its packaging a new look, and is currently working ... the public. , The new website, developed with Thread ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in ... Every Body Walk! campaign by Kaiser Permanente. ... workers to be more active outside of the workplace. ... the end of September, was a friendly competition between organizations ... Participating companies gave their staff pedometers and each day, for ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center for ... ROI on membership dues at 12.5. In other words, for ... value to member hospitals. The calculation used to determine member ... , “This is the first time we’ve actually been able ... is really sound,” said Bill Ryan , president and ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
... determined how to fortify the cassava plant, a staple ... minerals and protein to provide the poor and malnourished ... meal. , The researchers have further engineered the cassava ... viral threats and are refining methods to reduce cyanogens, ...
... no one key reason for a particular orientation, ... Genetics and random environmental factors each play a major ... British and Swedish researchers. , "This study puts ... for a single ,gay gene, or a single environmental ...
... - Based on Outstanding Quality and Compliance -, ... today announced that it has received the prestigious ... consecutive year. The,award recognizes outstanding performance in quality ... percent chosen as award winners. IL,was presented with ...
... PITTSBURGH, June 30 Circadiance launched the,revolutionary SleepWeaver(TM) ... 22nd,Annual Meeting of the Associated Professional Sleep Societies, ... - 12., Many sleep apnea patients discontinue ... irritation and sleep interruption. The,innovative SleepWeaver is the ...
... SXC Health Solutions Corp.,("SXC" or the "Company") (NASDAQ: ... of,technology and pharmacy benefits management services, announces a ... pharmacy benefit management,("PBM") services with The University of ... services for more than 6,000 members of,UT,s employee ...
... (TSX: MDS, NYSE:,MDZ), a leading provider of enabling products ... that the Toronto Stock Exchange,(TSX) accepted the Company,s Notice ... a one-year period., The Notice provides that during ... 2, 2009, if deemed appropriate by the Chief Executive,Officer ...
Cached Medicine News:Health News:Fortified cassava could provide a day's nutrition in a single meal 2Health News:Fortified cassava could provide a day's nutrition in a single meal 3Health News:Fortified cassava could provide a day's nutrition in a single meal 4Health News:Genetics, Environment Shape Sexual Behavior 2Health News:Instrumentation Laboratory Receives Performance Award from Premier for Second Consecutive Year 2Health News:Clinical Launch of Innovative Cloth Sleep Apnea Mask Creates Buzz at Sleep Conference 2Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 2Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 3Health News:MDS Inc. Announces Normal Course Issuer Bid 2
The WADiana Compact is a fully automated immuno-haematology analyser, easy to use with maximum security including clot detection and ensuring no contamination....
The Ortho AutoVue System is an automated immunohematology testing system used for blood typing, antibody screening and compatibility testing using Ortho BioVue System cassettes....
ABS2000 is an automated system that can handle more workload. It allows accurate detection of antibodies that can be missed out by manual testing....
... vision and disposable lens convenience for those ... and want crisp, clear vision with the ... Toric. Vertex Toric lenses are manufactured using ... produces a perfect edge on every lens. ...
Medicine Products: